



Cite this: *Chem. Sci.*, 2023, **14**, 11907

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 4th September 2023  
Accepted 9th October 2023

DOI: 10.1039/d3sc04660e  
[rsc.li/chemical-science](http://rsc.li/chemical-science)

## Unlocking mild-condition benzene ring contraction using nonheme diiron *N*-oxygenase†

Yuan-Yang Guo, \* Ze-Hua Tian, ChunHua Ma, Yu-Chen Han, DaChang Bai and ZhiYong Jiang

Benzene ring contractions are useful yet rare reactions that offer a convenient synthetic route to various valuable chemicals. However, the traditional methods of benzene contraction rely on noble-metal catalysts under extreme conditions with poor efficiency and uncontrollable selectivity. Mild-condition contractions of the benzene ring are rarely reported. This study presents a one-step, one-pot benzene ring contraction reaction mediated by an engineered nonheme diiron *N*-oxygenase. Using various aniline substrates as amine sources, the enzyme causes the phloroglucinol-benzene-ring contraction to afford a series of 4-cyclopentene-1,3-dione structures. A reaction detail study reveals that the nonheme diiron *N*-oxygenase first oxidizes the aromatic amine to a nitroso intermediate, which then attacks the phloroglucinol anion and causes benzene ring contraction. Besides, we have identified two potent antitumor compounds from the ring-contracted products.

## Introduction

Ring contractions (RCTs) are powerful tools for synthesizing atom-number-reduced structures from existing ring skeletons. Carbon-ring contractions provide elegant and efficient synthetic routes to many drugs, natural products, and industrial materials.<sup>1–5</sup> Among all carbon-ring structures, benzene is notably the most widely distributed one in nature, rendering it a promising reservoir for RCTs. Representative benzene ring contracted structures, such as cyclopentene and saturated cyclic hydrocarbons, carry substantial significance within the pharmaceutical and industrial domains (Fig. 1A).<sup>6,7</sup> However, owing to the aromaticity, non-polarity, and high stability, contracting or cleaving the benzene ring gives rise to inherent thermodynamic barriers. Current strategies for opening benzene rings require the involvement of specific functional groups, heavy metals, high temperature, electrochemical methods, or photochemical techniques, in order to overcome the inherent thermal barrier (representative examples in Fig. 1B).<sup>6–15</sup> Therefore, mild-condition enzymatic contraction of the benzene ring is of great importance and yet challenging. In this study, we report an

aqueous-phase phloroglucinol benzene RCT facilitated by an engineered non-heme diiron *N*-oxygenase, AzoC-III (Fig. 1C).

The typical prerequisites for RCT encompass four key elements: firstly, the imperative incorporation of activating factors like heat, nucleophilic reagents, Lewis acid, light, oxidation, or heavy metals;<sup>16–22</sup> secondly, the generation of active intermediates, be they ions, carbenoids, or radicals, in facilitating the contraction process;<sup>23–25</sup> thirdly, the strategic positioning of functional groups, such as sulfones, halogen




Fig. 1 Benzene ring contractions and cleavages. (A) Traditional benzene ring contraction in the petroleum industry. (B) Examples of current benzene ring cleavage strategies. (C) Non-heme diiron *N*-oxygenase mediated benzene ring contraction in this study.

State Key Laboratory of Antiviral Drugs, Collaborative Innovation Centre of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, China. E-mail: [guoyuanyang@163.com](mailto:guoyuanyang@163.com)

† Electronic supplementary information (ESI) available. CCDC 2193171 and 2209966. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3sc04660e>



atoms, diazole, azide, organic boron, organic silicon, thioether, enol ethers, vicinal diols, or enolized ketones, adjacent the contracting site;<sup>26</sup> fourthly, the requirement of a spontaneous or environmentally triggered chemical rearrangement, such as the pinacol rearrangement, Favorskii rearrangement, Wolff rearrangement, cyclic silyl-enol ether rearrangement, etc., in stabilizing the active intermediates and ensuring the fulfilment of the contractions.<sup>27–31</sup> With these fundamental elements, traditional RCTs often transpire under rigorous conditions, yielding intricate byproducts.

Non-heme diiron *N*-oxygenase AzoC natively catalyzes four-electron oxidation of an amine to a nitroso group during azoxymycins biosynthesis in *Streptomyces chattanoogensis*.<sup>32,33</sup> Recently, this enzyme's catalytic capability has been extended for the chemoenzymatic synthesis of phenol diarylamines employing its intrinsic nitroso-producing ability. Mechanistically, AzoC-II, the substrate-scope expanded AzoC mutant, catalyzes the four-electron oxidation of various *para*- and *meta*-substituted aniline substrates to afford the corresponding nitroso intermediates, which couple to the phenoxide anion (the enolized form of phenol) and culminate in the formation of the final diarylamine products.<sup>34</sup> In organic chemistry, the nitroso group is widely recognized as a versatile and captivating building block for forging C–N and N–N bonds.<sup>35–37</sup> Consequently, the nitroso group fulfils the role of the initial activating factor in the RCT process, while diarylhydroxylamine, an intermediate formed after nitroso addition to the phenoxide anion during phenol diarylamine biosynthesis, might contribute as the second element of the active intermediate; furthermore, the alkaline solution (pH 8 buffer) could potentially serve as the fourth element, inducing environmental phenol rearrangement.<sup>38</sup> By intertwining these principles, we investigated whether mild-condition RCT could be realized through this chemoenzymatic phenol  $sp^2$  C–H amination strategy.

## Results and discussion

### Enzymatic RCT design

Our investigation commenced by seeking an appropriate starting benzene ring substrate. In the context of diarylamine synthesis, the reactivity of phenol experiences a substantial elevation as the number of hydroxyl groups increases. For example, while a phenol with a solitary hydroxy group fails to yield diarylamine, introducing two hydroxy groups leads to a 78% diarylamine yield.<sup>34</sup> This observation led us to hypothesize that a benzene ring with three hydroxyl groups might exhibit heightened reactivity in benzene ring activation. Among benzene tri-phenols, phloroglucinol stands out because it possesses three chemically equivalent  $sp^2$  C–H bonds. This advantage could avoid the formation of undesired imbalanced chemical products. Hence, we selected phloroglucinol (**1**) as the model phenol substrate, and employed *p*-aminobenzoic acid (**2**) as the amine partner. We then conducted the enzymatic phenol amination reaction in pH 8 PBS buffer using phenazine methosulfate (PMS) as the electron mediator and glucose dehydrogenase (GDH) as the NADH regenerating system




Fig. 2 Enzyme triggered ring contraction of phloroglucinol. (A) AzoC mediated RCT. (B) HPLC analysis of the enzyme reaction mixtures at 305 nm (note: **1** is undetectable with our HPLC method). (i) Standard **2**; (ii) standard **4**; (iii) standard **5**; (iv) 100  $\mu$ M **2** with 1  $\mu$ M AzoC; (v) 50  $\mu$ M **1** and 100  $\mu$ M **2**, with 1  $\mu$ M boiled AzoC; (vi) 50  $\mu$ M **1** and 100  $\mu$ M **2**, with 2  $\mu$ M Mohr's salt (ferrous iron source); (vii) 50  $\mu$ M **1** and 100  $\mu$ M **2**, with 1  $\mu$ M AzoC. (C) X-ray structure of **3a** (CCDC ID: 2193171). Note: Standard **5** showed two peaks due to the spontaneous N=N E/Z isomerization of the azoxy bond.

(Fig. 2A).<sup>34</sup> A series of control reactions were performed as well. According to HPLC analysis, the enzyme predominantly transformed **2** to *p*-nitroso benzoic acid (**4**), as expected, when **1** was not added (Fig. 2B, trace iv); however, the incubation of **1** and **2** with AzoC resulted in the formation of a new peak **3** (Fig. 2B, trace vii) alongside the azoxy product (**5**, a non-enzymatic dimerization product from **4**, as reported previously).<sup>32,33</sup> Meanwhile, the incubation of **1** and **2** with boiled enzyme or ferrous ions showed no reaction (Fig. 2B, traces v and vi). These results indicated that both the nitroso-producing activity of AzoC and the presence of **1** are crucial for generating **3**. We then performed a scale-up reaction and purified **3**.  $^1$ H NMR analysis of **3** revealed a distinctive non-benzene chemical shift signal at 3.14 (Fig. S4†), which was absent in any substrates or characterized shunt products, suggesting a possible ring cleavage. To corroborate this finding, we further used 3-(4-aminophenyl) propionic acid and aniline as amine sources, and isolated **3a** and **3b**, respectively.  $^1$ H NMR analysis of **3a** and **3b** also unveiled non-benzene chemical shift signals at 3.06 and 3.08, respectively (Fig. S8 and S12†). We then referred **3**, **3a** and **3b** to single crystal cultivation and obtained the crystals of **3a** and **3b** in methanol solution (Fig. 2C, S7 and S11,† **3a** CCDC ID: 2193171, **3b** CCDC ID: 2209966).<sup>39</sup> The X-ray diffraction analysis indicated that both **3a** and **3b** comprised a 1,3-cyclopentanedione moiety, distinctly indicating a noticeable ring contraction of **1**. These results enabled the assignment of the  $^1$ H NMR signal around 3.1 as the hallmark chemical shift of the RCT products.

### Reaction conditions optimization

We then optimized the reaction conditions. With **1** and **2** as substrates, we analyzed the influences of buffer type, substrates ratio, and GDH stock addition on the yield of **3** (Table 1). As a result, optimal reaction conditions with a 96% yield of **3** were obtained when the reaction was performed by incubating **1** eq.



Table 1 Reaction conditions optimization

Entry	Buffer	1/2 ratio	GDH stock	Yield [%]
			[v/v]	
1	pH 7 PBS	1 : 2	0.1%	46
2	pH 8 PBS	1 : 2	0.1%	63
3	pH 9 PBS	1 : 2	0.1%	58
4	pH 8 PBS	1 : 2.5	0.1%	85
5	pH 8 PBS	1 : 3	0.1%	92
6	pH 8 PBS	1 : 4	0.1%	91
7	pH 8 PBS	1 : 5	0.1%	92
8	pH 8 HEPES	1 : 3	0.1%	96
9	pH 8 Tris-HCl	1 : 3	0.1%	94
10	pH 8 HEPES	1 : 3	0.2%	95
11	pH 8 HEPES	1 : 3	0.3%	96
12	pH 8 HEPES	1 : 3	0.5%	94
13	pH 8 HEPES	1 : 3	1%	93

of **1**, 3 eq. of **2**, 10% eq. of PMS, 10% eq. of TEMPO (nitroso polymerization inhibitor), 0.1% v/v GDH stock solution (electron source), and 3% mol enzyme in pH 8 HEPES buffer for 1 h (entry 8 in Table 1). Interestingly, the increase of the 2/1 ratio above 3 has not improved the yield of **3** and meanwhile has not caused the production of side-products other than **4** and **5** (entries 5–7 in Table 1 and Fig. S56†), which indicates **3** is the chemically stable ring contracting product rather than an active intermediate.

### Enzyme engineering

With the optimized reaction conditions in hand, we then set out to further expand the amine substrate scope of AzoC. AurF (GenBank accession number: CAE02601), a non-heme diiron *N*-oxygenase bearing 39% sequence identity to AzoC, can effectively oxidize a variety of *para*-, *meta*- and *ortho*-carboxy substituted aniline substrates to the corresponding nitro products.<sup>40,41</sup> In our phenol diarylamine biosynthetic study,<sup>34</sup> a mutant enzyme, AzoC-II, which recognizes various *para*- and *meta*-substituted anilines, was readily obtained through a simple two-substrate-binding-residues switch of AzoC to the counterpart-residues of AurF. Since AzoC-II does not accept *ortho*-substituted anilines, we further engineered this enzyme using AurF as the structural model. Bioinformatic analysis of AurF and AzoC revealed a residue difference in the substrate binding pocket (the red and blue marked amino acid residues in Fig. 3A). The co-crystal structure of AurF with *para*-nitrobenzoic acid (PDB:3-CHT, Fig. 3B) indicated the involvement of Y93, V97, T100, N200 and R302 in substrate-binding (corresponding to residues Y94, T98, L101, N202, and Q304 in AzoC).<sup>42</sup> Among these, Y93 and N200 in AurF are identical to their counterparts in AzoC. The R<sub>AurF</sub>304Q<sub>AzoC</sub> mutation, which replaced the basic amino acid R with the polar neutral amino




Fig. 3 Engineering and characterization of AzoC. (A) Sequence alignment of AurF, AzoC and AzoC-III. (B) Substrate binding pocket of AurF (PDB:3-CHT). (C) Substrate binding pocket of AzoC-III, the structure was built using SWISS-MODEL based on PDB:3-CHT. (D) UV/visible spectra of AzoC and AzoC-III at the diferric state: 10  $\mu$ M enzyme in pH 8 HEPES buffer was bubbled with oxygen for 5 min, then subjected to UV/vis analysis. (E) UV/vis spectra of AzoC and AzoC-III at the diferrous state: 10  $\mu$ M enzyme in pH 8 HEPES buffer was mixed with 5 fold sodium dithionite for 5 min, then subjected to UV/vis analysis. (F) CD spectra of AzoC and AzoC-III: 10  $\mu$ M enzyme in pH 8 HEPES was analyzed.

acid Q in AzoC, potentially explained the recognition of various *para*-substituted anilines by AzoC (AurF predominantly favors acid-substituted anilines). Thus, we narrowed our focus to residues T98 and L101. Considering that T98 and L101 in AzoC and V97 and T100 in AurF are all uncharged amino acids, we constructed a mutant library by replacing these two residues with smaller, uncharged amino acids. Following two rounds of screening, we successfully isolated the AzoC-T98G-L101G mutant (AzoC-III), which exhibited the broadest substrate scope encompassing diverse electronic substitution on *para*-, *meta*- and *ortho*-sites. The structural-mimic model of AzoC-III (Fig. 3C) indicates an enlarged substrate binding pocket compared to that of AurF (Fig. 3B). This potentially explains the extended substrate scope of AzoC-III.

### Identification of the mutant enzymes

The successful execution of the RCT reaction heavily relies on the enzymatic nitroso-producing activity. However, AzoC-III was engineered based on the nitro-producing enzyme AurF. In non-heme diiron oxygenases, the oxygen-iron coordination geometry is a critical determinant of the enzymatic reactivity.<sup>43,44</sup> UV/



vis spectra analysis is an effective method to characterize the oxygen–iron coordination. Consequently, our assessment delved into the UV/visible spectra analysis of both AzoC and AzoC-III, spanning their diferric (oxygen-coordinated to the diiron center, in the oxidizing form) and diferrous (no oxygen-coordinated to the diiron center, in the reducing form) states. As depicted in Fig. 3D and E, the UV/vis spectra of AzoC-III and AzoC closely aligned in both the diferric and diferrous states. This congruence underscored the substantial resemblance between the oxygen–iron coordination geometries of AzoC-III and AzoC. Essentially, the UV/visible data provided microstructural confirmation of the likeness at the active iron center between AzoC-III and the native enzyme AzoC. Considering that the activity of a metalloenzyme is influenced not only by the active metal center but also by the protein scaffold,<sup>45</sup> our exploration next extended to the macrostructural analysis of AzoC-III and AzoC by using circular dichroism (CD) spectroscopy, which is a powerful protein-secondary-structure investigation tool. As depicted in Fig. 3F, the negative bands at 208 nm and 222 nm in the spectra of both AzoC and AzoC-III signified the prevailing  $\alpha$ -helical structural characteristic. This insight indicated that the engineering of AzoC to AzoC-III did not disrupt the overall  $\alpha$ -helical protein scaffold at the macrostructural level. By examining these findings, it's clear that AzoC-III underwent changes neither in its protein scaffold nor in its active center. Instead, the changes should be centered around the substrate binding pocket.

### Substrate scope expansion

Subsequently, we studied the substrate scope of this RCT, utilizing AzoC-III as the catalyst under the optimized reaction conditions. As depicted in Fig. 4, our reaction converted a diverse array of aniline substrates, including varying electronic substitutions at the *para*-, *meta*-, and *ortho*-sites, to the RCT products in good to excellent yields. Upon delving into the regioselectivities, the *para*- and *meta*-substituted anilines gave excellent yields (3c–3g and 3h–3k in Fig. 4, respectively), while *ortho*-substituted anilines (3l–3o in Fig. 4) only showed good yields, indicating that even with the enzyme engineering, AzoC-III displays a regioselectivity bias against *ortho*-substitutions. Interestingly, in all *para*-, *meta*- and *ortho*-substitutions, anilines with higher water solubilities exhibited remarkably better yields (such as 3c, 3e, 3g, 3j, 3k, 3m and 3o) compared to those with lower water solubilities (such as 3d, 3f, 3h, 3i, 3l and 3n), the water solubilities were collected from the PubChem database<sup>46</sup>. This observation suggests that the water solubilities of anilines exert a more pronounced influence on this enzymatic RCT compared to their electron-inductive effects. In essence, the substrate scope examination revealed a broad tolerance for electronic substitution and a general capacity for regioselectivity of the aniline substrates, towards both the engineered enzyme AzoC-III and the RCT reaction itself.

### Reaction detail study

We then proceeded to study the reaction details in order to probe the potential mechanism. Aromatic nitroso groups




Fig. 4 Substrate scope of the RCT. Reaction conditions: 30  $\mu$ M AzoC-III, 100  $\mu$ M PMS, 100  $\mu$ M TEMPO, 1 mM phloroglucinol and 3 mM amines were incubated with 0.1% v/v GDH stock solution in pH 8 HEPES buffer at 25 °C and 200 rpm for 12 h.

exhibit both radical and ionic addition reactivities.<sup>47</sup> Strikingly, during our optimization efforts and the prior diarylamine biosynthesis studies, introducing a radical scavenger (TEMPO) into the reaction system resulted in enhanced but not decreased yields (Table 1). Hence, the possibility of a radical addition route was excluded, leaving the ionic addition pathway more credible. We then studied the authentic state of phloroglucinol (1) during the reaction. The structure of 1 indicated that it has various enol and keto tautomerizations. In pH 8 PBS buffer, the UV/vis spectrum of 1 exhibited absorbance peaks at 278 nm and 350 nm, corresponding to the mono-deprotonated and double-deprotonated phenoxide anion states of phloroglucinol respectively (Fig. 5A and B).<sup>48</sup> With all of this evidence, an ionic addition of the nitroso N atom (positively charged) onto the negatively charged phloroglucinol phenoxide anions was proposed. We then delved into unravelling the departing entity of the contracted carbon atom from the phloroglucinol benzene ring. The strategy started by incubating 3 mmol of nitrobenzene and 1 mmol of 1 in 50 mL HEPES buffer (pH 8) within a pre-degassed and sealed flask for an hour, followed by the adjustment of the solution pH to 4 and the collection of the expelled gas. Remarkably, the Gas Chromatography (GC) analysis of the expelled gas revealed a peak exhibiting the same retention time as CO<sub>2</sub> (Fig. S53†). Moreover, when the collected gas was bubbled through saturated limewater, a milky sediment was observed, the characteristic of CO<sub>2</sub> formation. These results






Fig. 5 Reaction detail study. (A) UV/vis spectrum of phloroglucinol (1) in pH 8 HEPES buffer. (B) Keto–enol tautomerization of phloroglucinol in pH 8 HEPES buffer. (C) Proposed pathway of the RCT.

firmly confirmed  $\text{CO}_2$  as the departing species of the contracted carbon atom. We further explored the hydrogen source of the secondary amine of the ring-contracted product. To elucidate this, we subjected nitrosobenzene and **1** to non-enzymatic reaction in pH 8  $\text{D}_2\text{O}$  water (pH adjusted using NaOD). A control reaction using  $\text{H}_2\text{O}$  and NaOH was conducted as well. High-resolution mass spectrometry (HRMS) analysis revealed a signal of +2 Da compared to the control sample (Fig. S54 and S55†), unequivocally establishing that the amine moieties' hydrogen atoms were originated from water. More importantly, the incubation of nitrosobenzene with **1** produced the RCT product **3b** at the equivalent yield (91%) to the enzymatic reaction, revealing a non-enzymatic chemical synthetic route of the RCT products. Based on these findings, a probable reaction pathway was proposed (Fig. 5C).

### Bioactivity study of RCT products

We proceeded to assay the bioactivities of the RCT products. As depicted in Fig. 4, the ring-contracted products **3b**–**3o** all share a common cyclopentenedione moiety, a versatile structure frequently encountered in natural products and drugs, particularly those exhibiting antimicrobial and anti-tumor activity.<sup>49–54</sup> Consequently, we evaluated their potent

bioactivities against *Staphylococcus aureus* ATCC 25923, *E. coli* K12, *Bacillus subtilis* ATCC 67736, *Saccharomyces cerevisiae* YJM789, breast cancer cell line MDA-MB-648, and lymphoma cell lines Rec-1 and RAMOS. Although the majority of the RCT products displayed negligible antimicrobial activity, we did observe mild activities of compound **3** against *S. aureus* ATCC 25923 ( $\text{MIC} \approx 125 \mu\text{M}$ , approximately 20 times that of chloramphenicol) and *E. coli* K12 ( $\text{MIC} \approx 25 \mu\text{M}$ , roughly 10 times that of chloramphenicol). We also observed moderate anti-tumor activities. Specifically, **3a** demonstrated moderate potency against RAMOS ( $\text{IC}_{50} \approx 3.150 \mu\text{M}$ , Fig. S57†), and **3g** displayed moderate effects against MDA-MB-648 ( $\text{IC}_{50} \approx 7.840 \mu\text{M}$ , Fig. S58†).

Beyond these bioactivities, cyclic dione structures hold significance as versatile building blocks within various domains of chemistry, including the synthesis of heterocycles, photoelectric materials, polymeric materials, organic catalysts, etc.<sup>55,56</sup> Moreover, diamine-substituted cyclopentane frameworks are pivotal moieties within asymmetric synthetic ligands and molecule recognition.<sup>57</sup> Conventional synthetic methodologies for cyclic diones and diamine-substituted cyclopentane frameworks necessitate multi-step metallic reactions in organic solvents.<sup>58–60</sup> In stark contrast, our RCT strategy offers an elegant and cutting-edge approach to these structures.

## Conclusions

In summary, we have demonstrated a benzene ring contraction (RCT) facilitated by an engineered non-heme diiron *N*-oxygenase. By utilizing phloroglucinol as the RCT starting material, the engineered enzyme AzoC-III showcases remarkable versatility in accommodating a wide array of aniline substrates. This encompasses an extensive range of electron-inductive substitutions on the *para*-, *meta*-, and *ortho*-sites of anilines, culminating in the generation of diverse RCT products. Remarkably, this process has led to the discovery of two promising anti-tumor compounds. Additionally, our findings have disclosed an efficient non-enzymatic method for the one-pot chemical synthesis of diamine-substituted cyclopentanenediones in an aqueous environment, utilizing nitroso compounds as nitrogen sources.

## Data availability

All data are provided in the ESI.†

## Author contributions

Y.-Y. G. conceived the idea and prepared the manuscript. Y.-Y. G., Z.-H. T. and Y.-C. H. performed the biosynthetic and mechanism experiments. C. H. M. and Y.-Y. G. performed the bioactivity study. D. C. B., Z. Y. J. and Y.-Y. G. conducted the mechanism experiments design.

## Conflicts of interest

There are no conflicts to declare.



## Acknowledgements

This work was supported by the National Natural Science Foundation of China (22377024, 31901014, 21925103) and the Natural Science Foundation of Henan Province (232300421229).

## References

- 1 K. M. J. de Mattos-Shipley, C. E. Spencer, C. Greco, D. M. Heard, D. E. O'Flynn, T. T. Dao, Z. Song, N. P. Mulholland, J. L. Vincent, T. J. Simpson, R. J. Cox, A. M. Bailey and C. L. Willis, *Chem. Sci.*, 2020, **11**, 11570–11578.
- 2 D. Heldt, A. D. Lawrence, M. Lindenmeyer, E. Deery, P. Heathcote, S. E. Rigby and M. J. Warren, *Biochem. Soc. Trans.*, 2005, **33**, 815–819.
- 3 L. F. Silva Jr, Ring Contraction Reactions in the Total Synthesis of Biologically Active Natural Products, *Stereoselective Synthesis of Drugs and Natural Products*, 2013, pp. 1–20, DOI: [10.1002/9781118596784.ssd018](https://doi.org/10.1002/9781118596784.ssd018).
- 4 X. Kang, G. Luo, L. Luo, S. Hu, Y. Luo and Z. Hou, *J. Am. Chem. Soc.*, 2016, **138**, 11550–11559.
- 5 L. F. Silva, Jr., *Molecules*, 2006, **11**, 421–434.
- 6 S. Hu, T. Shima and Z. Hou, *Nature*, 2014, **512**, 413–415.
- 7 D. S. Jones and P. P. Pujadó, *Handbook of petroleum processing*, Springer Science & Business Media, 2006.
- 8 X. Qiu, Y. Sang, H. Wu, X.-S. Xue, Z. Yan, Y. Wang, Z. Cheng, X. Wang, H. Tan, S. Song, G. Zhang, X. Zhang, K. N. Houk and N. Jiao, *Nature*, 2021, **597**, 64–69.
- 9 Y. Shimoyama, T. Ishizuka, H. Kotani and T. Kojima, *ACS Catal.*, 2019, **9**, 671–678.
- 10 L. T. Scott and N. H. Roelofs, *J. Am. Chem. Soc.*, 1987, **109**, 5461–5465.
- 11 L. T. Scott, N. H. Roelofs and T. H. Tsang, *J. Am. Chem. Soc.*, 1987, **109**, 5456–5461.
- 12 M. Jakoobi, N. Halcovitch, G. F. S. Whitehead and A. G. Sergeev, *Angew. Chem., Int. Ed.*, 2017, **56**, 3266–3269.
- 13 W. Guo, W. Ding, Y. Yao, S. Rajca, Q. Li, H. Jiang, A. Rajca and Y. Wang, *Org. Lett.*, 2023, **25**, 3972–3977.
- 14 Z.-C. Yin, M. Li, C. Niu, W.-F. Wang, W.-R. Liu, Q.-W. Zhang and G.-W. Wang, *Angew. Chem., Int. Ed.*, 2023, **62**, e202304321.
- 15 J. Jian, X. Wu, M. Chen and M. Zhou, *J. Am. Chem. Soc.*, 2020, **142**, 10079–10086.
- 16 N. E. Behnke, J. H. Siionen, S. A. Chamness and L. Kürti, *Org. Lett.*, 2020, **22**, 5715–5720.
- 17 Z. Huang, W.-X. Zhang and Z. Xi, *Org. Lett.*, 2018, **20**, 485–488.
- 18 K. Hurej, M. Pawlicki, L. Szterenberg and L. Latos-Grażyński, *Angew. Chem., Int. Ed.*, 2016, **55**, 1427–1431.
- 19 J. Jurczyk, M. C. Lux, D. Adpressa, S. F. Kim, Y.-h. Lam, C. S. Yeung and R. Sarpong, *Science*, 2021, **373**, 1004–1012.
- 20 B. Patra, S. Sobottka, S. Mondal, B. Sarkar and S. Kar, *Chem. Commun.*, 2018, **54**, 9945–9948.
- 21 E. Tayama, Ring-Substitution, Enlargement, and Contraction by Base-Induced Rearrangements of *N*-Heterocyclic Ammonium Salts, *Heterocycles*, 2016, **92**, 793–828.
- 22 X. Yu, J. Hu, Z. Shen, H. Zhang, J.-M. Gao and W. Xie, *Angew. Chem., Int. Ed.*, 2017, **56**, 350–353.
- 23 D. Crich, A. L. J. Beckwith, G. F. Filzen and R. W. Longmore, *J. Am. Chem. Soc.*, 1996, **118**, 7422–7423.
- 24 M. Piesch, S. Reichl, M. Seidl, G. Balázs and M. Scheer, *Angew. Chem., Int. Ed.*, 2019, **58**, 16563–16568.
- 25 K. Takasu, Y. Nagamoto and Y. Takemoto, *Chem.-Eur. J.*, 2010, **16**, 8427–8432.
- 26 Z.-L. Song, C.-A. Fan and Y.-Q. Tu, *Chem. Rev.*, 2011, **111**, 7523–7556.
- 27 D. Bégué, H. Santos-Silva, A. Dargelos and C. Wentrup, *J. Phys. Chem. A*, 2017, **121**, 5998–6003.
- 28 C. Chapuis, F. Robvieux, C. Cantatore, C. Saint-Léger and L. Maggi, *Helv. Chim. ACTA*, 2012, **95**, 428–447.
- 29 J. Limanto, E. R. Ashley, J. Yin, G. L. Beutner, B. T. Grau, A. M. Kassim, M. M. Kim, A. Klapars, Z. Liu, H. R. Strotman and M. D. Truppo, *Org. Lett.*, 2014, **16**, 2716–2719.
- 30 M. J. Mitcheltree, Z. A. Konst and S. B. Herzon, *Tetrahedron*, 2013, **69**, 5634–5639.
- 31 J. Oliver-Meseguer, M. Boronat, A. Vidal-Moya, P. Concepción, M. Á. Rivero-Crespo, A. Leyva-Pérez and A. Corma, *J. Am. Chem. Soc.*, 2018, **140**, 3215–3218.
- 32 Y.-Y. Guo, H. Li, Z.-X. Zhou, X.-M. Mao, Y. Tang, X. Chen, X.-H. Jiang, Y. Liu, H. Jiang and Y.-Q. Li, *Org. Lett.*, 2015, **17**, 6114–6117.
- 33 Y.-Y. Guo, Z.-H. Li, T.-Y. Xia, Y.-L. Du, X.-M. Mao and Y.-Q. Li, *Nat. Commun.*, 2019, **10**, 4420.
- 34 Y.-Y. Guo, Z.-H. Li, L. Wang, Z.-D. Lai, L. Li and Y.-Q. Li, *ACS Catal.*, 2023, **13**, 1412–1417.
- 35 H.-Y. He, H. Niikura, Y.-L. Du and K. S. Ryan, *Chem. Soc. Rev.*, 2022, **51**, 2991–3046.
- 36 A. J. Waldman, T. L. Ng, P. Wang and E. P. Balskus, *Chem. Rev.*, 2017, **117**, 5784–5863.
- 37 Y. Katsuyama and K. Matsuda, *Curr. Opin. Chem. Biol.*, 2020, **59**, 62–68.
- 38 M. Murakata and M. Kimura, *Tetrahedron Lett.*, 2010, **51**, 4950–4952.
- 39 Deposition numbers 2193171 and 2209966 contain the supplementary crystallographic data for this paper.†
- 40 E. Chanco, Y. S. Choi, N. Sun, M. Vu and H. Zhao, *Helv. Chim. Acta*, 2014, **22**, 5569–5577.
- 41 R. Winkler, M. E. A. Richter, U. Knuepfer, D. Merten and C. Hertweck, *Angew. Chem., Int. Ed.*, 2006, **45**, 8016–8018.
- 42 Y. S. Choi, H. Zhang, J. S. Brunzelle, S. K. Nair and H. Zhao, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 6858–6863.
- 43 A. J. Jasniewski and L. Que, *Chem. Rev.*, 2018, **118**, 2554–2592.
- 44 T. M. Makris, V. V. Vu, K. K. Meier, A. J. Komor, B. S. Rivard, E. Muenck, L. Que, Jr. and J. D. Lipscomb, *J. Am. Chem. Soc.*, 2015, **137**, 1608–1617.
- 45 A. J. Reig, M. M. Pires, R. A. Snyder, Y. Wu, H. Jo, D. W. Kulp, S. E. Butch, J. R. Calhoun, T. Szyperski, E. I. Solomon and W. F. DeGrado, *Nat. Chem.*, 2012, **4**, 900–906.



46 S. Kim, P. A. Thiessen, E. E. Bolton, J. Chen, G. Fu, A. Gindulyte, L. Han, J. He, S. He, B. A. Shoemaker, J. Wang, B. Yu, J. Zhang and S. H. Bryant, *Nucleic Acids Res.*, 2016, **44**, D1202–D1213.

47 Y. Gao, S. Yang, W. Xiao, J. Nie and X.-Q. Hu, *Chem. Commun.*, 2020, **56**, 13719–13730.

48 M. Lohrie and W. Knoche, *J. Am. Chem. Soc.*, 1993, **115**, 919–924.

49 L. Chen, B. Liu, J.-J. Deng, J.-S. Zhang, W. Li, A. Ahmed, S. Yin and G.-H. Tang, *RSC Adv.*, 2018, **8**, 17898–17904.

50 H. Tan, C. Zheng, Z. Liu and D. Z. Wang, *Org. Lett.*, 2011, **13**, 2192–2195.

51 S.-H. Gao, Y.-X. Jia, X.-Z. Zhao and Y.-Q. Tu, *Chin. J. Chem.*, 2006, **24**, 595–597.

52 S. Das, S. Chandrasekhar, J. S. Yadav and R. Grée, *Chem. Rev.*, 2007, **107**, 3286–3337.

53 T. Das, P. Saha and V. K. Singh, *Org. Lett.*, 2015, **17**, 5088–5091.

54 H. Pellissier, *Chem. Rev.*, 2016, **116**, 14868–14917.

55 K. De Bruycker, S. Billiet, H. A. Houck, S. Chattopadhyay, J. M. Winne and F. E. Du Prez, *Chem. Rev.*, 2016, **116**, 3919–3974.

56 D. B. Rubinov, I. L. Rubinova and A. A. Akhrem, *Chem. Rev.*, 1999, **99**, 1047–1066.

57 J. González-Sabín, F. Rebollo and V. Gotor, *Chem. Soc. Rev.*, 2009, **38**, 1916–1925.

58 A. Jeppesen, B. E. Nielsen, D. Larsen, O. M. Akselsen, T. I. Sølling, T. Brock-Nannestad and M. Pittelkow, *Org. Biomol. Chem.*, 2017, **15**, 2784–2790.

59 V. E. Zwicker, K. K. Y. Yuen, D. G. Smith, J. Ho, L. Qin, P. Turner and K. A. Jolliffe, *Chem.-Eur. J.*, 2018, **24**, 1140–1150.

60 H. Junek, G. Zuschnig, R. Thierichter, G. Gfrerer and H. Sterk, *Monatsh. Chem.*, 1982, **113**, 1045–1058.

